Search

for
Search:

Glossary

Similar Terms

Learn

0 / 0 results

— no results

Research

5 / 1000+ results

research Polycystic Ovary Syndrome: Etiology, Pathogenesis, and Diagnosis

991 citations, January 2011 in “Nature Reviews Endocrinology”

The document concludes that PCOS is a complex disorder caused by both genetic and environmental factors, affecting women's health in various ways, and requires personalized treatment.

research Reconsidering PCOS Etiology, Diagnosis, Clinical Subgroups, and Subgroup-Specific Treatments

January 2024 in “Endocrine and metabolic science”

Different types of PCOS need specific diagnosis methods and treatments.

research Platelet-Rich Plasma: A Promising Regenerative Therapy in Gynecological Disorders

3 citations, September 2022 in “Cureus”

Platelet-rich plasma shows promise for treating various female reproductive health issues but requires more research.

research Polycystic Ovary Syndrome: Comprehensive Overview

257 citations, July 2018 in “Obstetrics & Gynecology”

PCOS is a complex disorder in women that can lead to various health risks and requires personalized treatment.

research Evidence-Based and Potential Benefits of Metformin in Polycystic Ovary Syndrome: A Comprehensive Review

343 citations, December 2008 in “Endocrine Reviews”

Metformin helps with menstrual cycles and insulin levels in PCOS but is less effective for hair growth, diabetes prevention, and weight loss, and may improve fertility and reduce diabetes risk.

View more "endometrial abnormalities" in research →

Community Join

2 / 2 results

community Taking Charge of Your Hair: The "Big 3 Stack" Explained for 2023

in Research/Science 129 upvotes 1 year ago

The "Big 3 Stack" for hair loss treatment, which includes Minoxidil for hair density improvement, Ketoconazole shampoo for enhancing hair volume and thickness, and Finasteride for blocking hair loss causing hormones. Microneedling can boost Minoxidil's effects.

community The story of RU58841/ PSK3841

in Research 622 upvotes 3 months ago

RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.